The FDA has authorised updated versions of Pfizer/BioNTech and Moderna's mRNA-based COVID-19 vaccines targeting the XBB.1.5 subvariant, in time for the start of a new autu
Just a few months after suggesting it may not survive to the end of 2023, Novavax has posted improved finances and a second-quarter profit, as it readies the launch of an
A malaria vaccine developed by members of the University of Oxford team that created the AstraZeneca COVID-19 jab has been approved in its first market, Ghana.
Flying into London recently for the Jefferies Conference, Novavax’s EVP, chief commercial officer, and chief business officer John Trizzino, together with the company’s ch
Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA's Vaccines and Related Biological Produc
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho